212 related articles for article (PubMed ID: 26008753)
21. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract][Full Text] [Related]
22. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
23. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
[TBL] [Abstract][Full Text] [Related]
24. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract][Full Text] [Related]
25. Secreted Frizzled-Related Protein 3 (SFRP3) Is Required for Tumorigenesis of PAX3-FOXO1-Positive Alveolar Rhabdomyosarcoma.
Kephart JJ; Tiller RG; Crose LE; Slemmons KK; Chen PH; Hinson AR; Bentley RC; Chi JT; Linardic CM
Clin Cancer Res; 2015 Nov; 21(21):4868-80. PubMed ID: 26071485
[TBL] [Abstract][Full Text] [Related]
26. Sphingosine Induces Apoptosis and Down-regulation of
Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K
Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758
[TBL] [Abstract][Full Text] [Related]
27. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
Kelly KM; Womer RB; Sorensen PH; Xiong QB; Barr FG
J Clin Oncol; 1997 May; 15(5):1831-6. PubMed ID: 9164192
[TBL] [Abstract][Full Text] [Related]
28. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis.
Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM
Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562
[TBL] [Abstract][Full Text] [Related]
29. RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy.
Rengaswamy V; Zimmer D; Süss R; Rössler J
J Control Release; 2016 Aug; 235():319-327. PubMed ID: 27261335
[TBL] [Abstract][Full Text] [Related]
30. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH;
Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077
[TBL] [Abstract][Full Text] [Related]
31. Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer.
Chay DB; Han GH; Nam S; Cho H; Chung JY; Hewitt SM
Int J Clin Oncol; 2019 Nov; 24(11):1429-1439. PubMed ID: 31302815
[TBL] [Abstract][Full Text] [Related]
32. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
33. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
Barr FG; Smith LM; Lynch JC; Strzelecki D; Parham DM; Qualman SJ; Breitfeld PP
J Mol Diagn; 2006 May; 8(2):202-8. PubMed ID: 16645206
[TBL] [Abstract][Full Text] [Related]
34. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
35. FOXO1-FGFR1 fusion and amplification in a solid variant of alveolar rhabdomyosarcoma.
Liu J; Guzman MA; Pezanowski D; Patel D; Hauptman J; Keisling M; Hou SJ; Papenhausen PR; Pascasio JM; Punnett HH; Halligan GE; de Chadarévian JP
Mod Pathol; 2011 Oct; 24(10):1327-35. PubMed ID: 21666686
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
37. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
[TBL] [Abstract][Full Text] [Related]
38. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
39. PAX--FKHR fusion genes and AChR-gamma in Chinese patients with rhabdomyosarcoma: diagnosis using formalin-fixed archival tissues.
Chang B; Pang LJ; Qi Y; Liu CX; Cao Y; Li HA; Hu WH; Jiang JF; Zhang WJ; Li F
Int J Surg Pathol; 2009 Feb; 17(1):6-15. PubMed ID: 18988640
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]